Tracking sinusitis control: a German registry study
Part of Ear, nose & throat, Lungs & breathing clinical trials.
This study is a registry that tracks how well treatments work for people with chronic rhinosinusitis with nasal polyps. By joining, you help doctors learn which therapies lead to better control and possibly remission of symptoms over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have been diagnosed with chronic rhinosinusitis (ongoing sinus inflammation) by a doctor.
- You (or a parent or guardian) are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new questionnaire to better understand chronic sinusitis symptoms. It may help improve how doctors diagnose and treat the condition.
This study tests a special nose dressing that slowly releases a steroid to reduce inflammation and improve healing after sinus surgery for chronic sinusitis with or without nasal polyps.
This study tests a new sinus stent that slowly releases medicine to treat chronic sinusitis in both nostrils. The goal is to see if it helps reduce symptoms and inflammation better than usual care.
This study follows people with chronic rhinosinusitis and nasal polyps who are starting a biologic medication (omalizumab, mepolizumab, or dupilumab) to see how well it works in real life.
This trial is a registry that enrolls people with severe, hard-to-control chronic sinusitis. It helps doctors better understand this specific type of inflammation and how it affects symptoms and quality of life.
This study is looking at healthy people to understand how certain cells in the nose work. It will compare them to people with sinus problems to learn what goes wrong in chronic sinusitis with nasal polyps.
Hear when a new Chronic Rhinosinusitis (CRS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.